Introduction
The low sensitivity of ultrasonography (US) in diagnosing axillary lymph node metastasis in breast cancer patients has sparked the evaluation of various tools in an attempt to increase pre-operative sensitivity. We compared axillary lymph node metastasis probability scores with post-surgical findings, using the Memorial Sloan Kettering Cancer Centre (MSKCC) nomogram and Evidencio, two freely available online predictor tools. Methods We retrospectively evaluated 450 breast cancer patients and analysed data from 194 patients. Ultrasound images were evaluated to assess axillary lymph node status. Patients were divided into groups 0, 1 or ≥2 nodes based on the number of post-operative positive nodes. The difference in mean scores across the 3 nodal groups for both nomograms was analysed using the one-way ANOVA test. The Nottingham Prognostic Index (NPI) was also calculated for each patient. Data was analysed using SPSS ver20 and p<0.05 was considered statistically significant. Results There were significant differences in mean scores across the 3 nodal groups when using MSKCC (p= 0.000), and Evidencio (p= 0.000). A strong positive correlation was found between MSKCC, Evidencio and NPI. (r s = 0.671 (MSKCC vs. Evidencio), r s = 0.721 (Evidencio vs. NPI), r s = 0.656 (MSKCC vs. NPI), p= 0.000 (for all)). Conclusion Both MSKCC and Evidencio nomograms can be used to predict axillary node metastasis and guide patient management. Further evaluation is recommended before omitting Sentinel Lymph Node Biopsy or Axillary Node Dissection in patients with very low scores and prompting a 'second look' US in patients with high scores. Introduction Pre-operative staging of the axilla is mandated. In 2011 the ACOSOG Z0011 trial indicated that women with small (T1 -T2) breast cancers and ≤2 nodes positive at SLNB may not require axillary clearance, resulting in a change to surgical practice. Pre-operative ultrasound is still routine despite studies showing between 38% and 46% of symptomatic women with positive pre-operative staging had ≤2 nodes positive at surgery and were thus potentially overtreated or eligible for the POSNOC trial. We measured the impact of current staging in one UK breast screening service. Method Data were extracted from the unit's National Breast Screening computer System between 01/04/2008 and 31/03/2015. Axillary staging was compared with final pathology and treatment. Results 164 of 776(21.1%) invasive cancers were node positive. 90 (11.6%) had an axillary biopsy, 54 were positive for cancer (32.9% of the node positive cases). Of these 22 (40.7%) had neoadjuvant treatment, 32 (59.3%) proceeded directly to axillary clearance (mean node count 14.6). 17 (53%) of those who had axillary clearance had ≤2 positive nodes. This compares with 82% of node positive women with a negative biopsy and 74% of node positive women with a normal ultrasound. Summary This small series suggests significant numbers of women are being denied entry into POSNOC or being potentially overtreated because of routine pre-operative axillary staging. A much larger data set is required to confirm this and predict who would benefit from preoperative axillary staging. A bid to use the whole ABS data set is with CRUK. 
To determine the rate and classification of interval breast cancer (IC) in the two years preceeding and following the introduction of digital mammography in 2011 in a national screening programme. Methods Two 2-year bands were used to ensure completed data for pre and post digital groups. Retrospective analysis of a prospectively collected database of IC was undertaken, identifying women who had undergone screening in the two years prior to and after the introduction of digital screening mammography (1.1.10 until 31.12.11 and 1.1.12 until
In the Republic of Ireland, national quality assurance standards state that patients over the age of 35 presenting with breast symptoms should routinely have two-view mammogramography. Our aim was to determine the breast cancer detection rate in women aged 35-39 with low risk factor profiles and normal clinical examinations. Methods A retrospective analysis of all mammograms performed in patients aged 35-39 at our institution from 2011-2015 was performed. Patients with moderate or high familial risk, previous breast cancer or chest radiation, males, GP and internal hospital referrals, and those with abnormal clinical examinations were excluded. Included women had "normal", "benign" or undocumented examinations. Results of imaging including subsequent ultrasound and histopathological information was obtained from EPR and PACS systems. Results 4,087 patients aged 35-39 had bilateral mammograms from 2011-2015. 2,149 patients were excluded from analysis. Of 1,938 included women, 4 (0.21%) were diagnosed with breast cancer confirmed at histology: 2 cases of invasive ductal carcinoma (8 and 2mm) and 2 of DCIS (4.5mm high-grade-DCIS and 2mm lowgrade-DCIS). Other histological findings included 2 B3, 40 B2 and 2 B1 lesions resulting from mammographic screening. Overall, 114 biopsies were performed; biopsy rate of 6.09%. 69 (60.53%) were undertaken due to mammographic findings. Conclusion 2.1 cases of cancer were detected per 1000 women screened. This figure would be below accepted international thresholds to undertake screening mammography and raises radiation protection issues. Additionally, a large number of benign biopsies were performed with inherent anticipated psychological impact. Further studies could inform national guidance.
Introduction NHSBSP standards for assessment recall in prevalent screen is a minimum of <10% with a target of <7%. Aims:
(i) review variation in recall rate
(ii) assess differences in practice and learn from units performing well
Methods
Prevalent recall rate for the last 3 years in units were collated and a questionnaire titled 'NHSBSP Prevalent Round Survey' designed with units invited to partake on Survey Monkey. Results Only 24% (19/80) of units achieved a prevalent recall rate of <7% for 3 consecutive years and 25% (20/80) of units had a recall of ≥10% at least once in the last 3 years. In total, 49% (39/80) of units responded:
Reader skill mix and volume (i) in units with recall of ≥10%, 86% (6/7) have <50% consultant radiologists in film reading team, compared with 22% (7/32) in units with a recall of <10%. (ii) in 67% (14/21) of units with recall of <7%, all readers achieved target of ≥5,000 mammograms/year, compared with 44% (8/18) in units with ≥7%.
Prevalent arbitration (i) 5% (2/39) have specific prevalent arbitration with arbitration of all potential recalls. (ii) 21% (8/39) have a policy for lesion types that do not require recall; 22% (7/32) with recall <10% and 14% (1/7) with recall ≥10%. This includes benign masses, physiological asymmetries and scattered benign calcifications.
Conclusion
Units with lower prevalent recall rates have a higher proportion of consultant radiologists and higher volume readers. Policy for lesions that do not require recall can reduce unnecessary assessment of benign lesions.
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Visual assessment of breast density: intra-and inter-observer variability in visual analogue scale scores Introduction Breast density is a strong risk factor for breast cancer and has potential use in breast cancer risk prediction, with subjective methods of density assessment providing a strong relationship with the development of breast cancer. This study aims to assess intra-and inter-observer variability in visual density assessment recorded on Visual Analogue Scales (VAS) among 11 trained readers, and hence the reproducibility over time.
Methods 11 readers of varying years of experience estimated the breast density of 120 mammograms on two occasions 3 years apart using VAS. Percent breast density was estimated on VAS score sheets and were scanned using custom software which converted the marks to percentages. Intra-and inter-observer agreement was assessed with intraclass correlation coefficient (ICC) and variation between readers visualised on Bland-Altman plots. Results Excellent intra-observer agreement (ICC>0.81) was found in majority of the readers. All but one reader had a mean difference <10 percentage points from the first to second reading. Inter-observer agreement was excellent for consistency (ICC 0.82) and substantial for absolute agreement (ICC 0.69). However, the 95% limits of agreement for pairwise differences were (-6.8 to 15.7) at the narrowest and (0.8 to 62.3) at the widest. Conclusion Overall, the readers were consistent in their scores, although some large inter-observer variations were observed. Reader evaluation and targeted training may alleviate this problem. Intra-observer readings are reliable and may be used in monitoring change in breast density over time, for example when assessing the efficacy of chemopreventive therapies.
Introduction
To assess the performance and accuracy of pre-operative Ultrasound evaluation of axillary lymph nodes in patients with breast cancer.
Methods
All patients who underwent wide local excision or mastectomy for invasive primary breast carcinoma in a UK district general hospital between July-Dec 2015 were identified retrospectively and included in the study. Patients who underwent neo-adjuvant chemotherapy were excluded from the study.
Results
Out of 94 patients with invasive breast carcinoma included in the study, 38 patients had abnormal axillary nodes on ultrasound and subsequent ultrasound guided axillary nodal biopsy (UANB), of which 16 had metastatic carcinoma from primary invasive breast carcinoma which was later confirmed on axillary nodal clearance (ANC). The remaining 22 patients underwent sentinel lymph node biopsy (SLNB) and had no malignant cells on histology.
Of the 56 patients who had normal pre-operative axillary ultrasound, 11 patients were found to have axillary nodal metastatic disease and 45 patients had no malignant cells on subsequent SLNB. In total, 27(n=94) patients were found to have axillary nodal metastases in our study. The positive predictive value of preoperative UANB in detecting axillary nodal metastatic disease is 42% (16/38) and the negative predictive value is 80% (45/56). The sensitivity of axillary ultrasound biopsy is 59% (16/27) and specificity is 67% (45/67). There were 22 false positive cases and 11 false negative cases.
Conclusion
The performance and accuracy of pre-operative ultrasound guided axillary nodal biopsy in detecting metastatic axillary nodal disease in our unit remains acceptable within published standards.
PB.2
Preoperative sentinel lymph node identification, biopsy and localization using contrast enhanced ultrasound (CEUS) in patients with breast cancer, a systematic review and meta-analysis Anne Nielsen Moody 
Introduction
Sentinel lymph node biopsy (SLNB) is the gold standard for axillary staging. Contrast enhanced ultrasound (CEUS), is a new technique for pre-operative identification, localization and biopsy of SLNs. Objective Evaluate, in patients with breast cancer and normal axillary B-mode ultrasound, whether: 1) CEUS guided core biopsy of the SLN could identify metastatic nodes pre-operatively and reduce the number of surgical SLNBs. 2) establish whether CEUS SLN identification and localization is a viable alternative to standard lymphatic mapping using isotope and blue dye. Methods Search of several electronic databases performed. Methodological quality assessed using QUADAS-2. Pooled estimate of sensitivity and specificity for identification of nodal metastases were calculated. Results Eleven prospective and one retrospective studies with 1520 participants were included. The SLN identification and localization rate for CEUS guided skin marking was 70% -100%, CEUS guided wire localization 89% -97% and CEUS guided I-125 seed localization 60%. Across the four studies which evaluated preoperative CEUS guided SLN biopsy, pooled sensitivity for identification of nodal metastases was 54% (95% CI: 47 -61) and pooled specificity 100% (CI: 99 -100). Conclusion CEUS is a promising technique for pre-operative staging of the axilla. CEUS guided core biopsy has the potential to identify nodal metastases in over half (54%) of patients with normal axillary B-mode ultrasound. CEUS guided identification and localization of the SLN may offer a viable alternative to standard lymphatic mapping using isotope and blue dye, however, further prospective studies with larger samples are warranted.
PB.3
Radiological staging of the axilla: a mixed response? Natalia Roszkowski, Alexis Grima, Michaela Stahnke, Caroline Rubin, Ruth Walker, Rachel Oeppen University Hospital Southampton, Southampton, UK Correspondence: Natalia Roszkowski Breast Cancer Research 2016, 18(Suppl 1):PB.3
Accurate assessment of axillary nodes in patients with breast cancer influences MDT recommendations about primary therapy, axillary surgery and additional investigations. Ultrasound with image-guided needle biopsy of abnormal nodes is recommended by NICE and cited in the DoH Best Practice Guidelines. Does improved sensitivity of axillary imaging increase the rate of referral for staging investigations? A completed audit loop evaluated the sensitivity and PPV of axillary ultrasound and image-guided node sampling in consecutive primary breast cancer cases in 2014 and 2012 at the breast imaging unit of a large teaching hospital. Results were compared with published data and the impact on rate of preoperative CT staging and detection of distant metastatic disease was assessed. Between 2012 (n=47) and 2014 (n=270) overall sensitivity of axillary ultrasound for metastatic nodes increased from 20% to 38%, achieving 95% sensitivity for patients with >1 abnormal node on ultrasound and 61% sensitivity for those with >2 positive nodes at surgery. Between the two audits PPV increased from 40% to 68% and the number of needle biopsies performed significantly increased, yielding a sensitivity of 79% (22/28) in 2014. Referral for pre-treatment staging CT also increased with positivity rate for distant metastases decreasing from 17% to 11% (7/65). Significantly improved sensitivity and PPV of axillary node ultrasound and needle biopsy are attributed to raised awareness of published data and MDT expectations and feedback. This has resulted in increased referral for pre-operative staging CT with a concomitant decrease in rate of detection of distant metastatic disease.
Introduction
Preoperative Ultrasound (US) assessment of axillary nodes is crucial in tailoring management of breast lesions and saves costs and time.
US Sensitivity for detection of metastatic axillary lymph nodes ranges from 54.1 % to 68.2%. At this DGH, cut offs for abnormal axillary lymph nodes were frankly abnormal features or a cortical thickness of 2.5mm or greater. This audit/review assessed axillary scanning in the context of biopsied suspicious breast lesions at a DGH SBC.
Methods
The DGH SBC collects a list of all biopsy cases. Data was obtained using this list, RIS and clinical portal for the time period 1 January 2015-1 December 2015. The following standard was utilised and assessed -"Ultrasound should identify nodes with metastatic involvement with 50% sensitivity (RCR)." The percentage of breast biopsy cases that also received US axilla assessment at the same time and agreement between axillary US/ Biopsy and histopathology were also reviewed. Recommended local improvement of focusing towards performing US in all microcalcification cases-to look for an invasive focus for US biopsy (rather than stereotactic) with axillary scanning at the same time.
PB.5
Axillary tumour burden in women with early breast cancer and 1 abnormal node on ultrasound scan compared with those with 2 or more abnormal nodes Shama Puri 1 Background The role of axillary node clearance (ANC) in patients with 1 or 2 positive sentinel nodes is being questioned in the POSNOC trial. Increasing sensitivity of axillary ultrasound has resulted in identifying preoperatively more lymph node positive patients and thereby fewer differences with sentinel node positive patients. The aim of this study was to determine if the number of abnormal nodes seen on preoperative axillary ultrasound correlates with the axillary tumour burden on histopathology after ANC, and whether this information can be used to identify patients with low volume disease who may be offered sentinel node biopsy(SNB) rather than ANC. Methods 66 patients with FNA or core biopsy proven axillary nodal metastasis were included in this prospective study from 4 centres. The number of abnormal nodes at pre-operative ultrasound examination was recorded (score of ≥3). All patients underwent ANC. Results 31 patients had 1 abnormal node and 35 patients ≥2 abnormal nodes on ultrasound scan. The median number of positive nodes found on pathology was 2(range 1-9) in patients with 1 abnormal node and 5(range 1-33) in patients with ≥2 abnormal nodes (p<.0001). 20 of 31 patients(64.5%) with 1 abnormal node on ultrasound had ≤3 positive nodes at ANC. 18 of 31 patients(58.1%) with 1 abnormal node had only 1 or 2 positive nodes at ANC. Conclusion Patients with 1 abnormal node seen on ultrasound can be offered SNB rather than ANC as the initial axillary surgery avoiding overtreatment and unnecessary arm morbidity in a significant number of patients.
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Preoperative axillary staging in breast cancer: a comparison of the sensitivity of fine needle aspiration biopsy and core needle biopsy Ashley Topps 1 , Simon Barr 1 , Panagiotis Pikoulas 1 , Susan Pritchard 1 , Anthony Maxwell Introduction Identifying axillary lymph node metastases preoperatively can inform discussions about neoadjuvant chemotherapy and also allow a patient to proceed to an axillary lymph node dissection (thus avoiding an additional sentinel node biopsy procedure). A meta-analysis has not shown a statistically significant difference in sensitivity between axillary US-guided fine needle aspiration biopsy (FNA) and core needle biopsy (CNB) 1 . Moreover, previous studies on this subject have only included low numbers of patients. Our aim was to directly compare the sensitivity of the two techniques. Method Patients with macrometastic nodal involvement treated at a tertiary referral centre between January 2012 and December 2015 were retrospectively identified from pathology records. The preoperative (first attempt) FNA and CNB results were compared to post-operative histopathology results. Results A total of 114 CNB's and 229 FNA's were performed. There were 87 true positive CNB's and 147 true positive FNA's. US-guided CNB was therefore more sensitive than US-guided FNA (76.3% vs. 64.2%, p = <0.05). There were 9 inadequate results in the CNB group and 16 in the FNA group (7.9% and 7.0%, respectively).A single haematoma requiring non-operative management was recorded in the CNB group. Conclusion US-guided CNB of the axilla is more sensitive than US-guided FNA and is a safe technique in experienced hands. 
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Background
In the era of Z0011, current practice of axillary node clearance for preoperative US detected lymph node metastasis will result in overtreatment of the axilla as some of these patients only have 1-2 positive nodes. Methods Patients with lymph node positive, newly diagnosed invasive breast cancer, during 2012-2014 at UHCW were selected retrospectively. Abnormal nodes defined by local criteria underwent ultrasound-guided FNA or core biopsy. Patients were grouped into 1-2 or 3 or more nodes (3+) based on their lymph node metastasis burden after ALNC, and tumour characteristics compared. Categorical variables were evaluated with chi-squared and Fisher's exact tests. Results 556 patients were diagnosed with invasive cancer, of which 210 had lymph node metastasis. 64 patients were found preoperatively (30.5%) and progressed to ALNC. However, 20 patients (31.3%) had only 1-2 positive nodes. Significantly more in the 1-2 node group underwent breast conserving surgery compared with the 3+ group, 65% versus 25% (p=0.002), and less had T3 cancers, 0% vs 22%, (p=0.024). The 1-2 node group also had a lower proportion of lymphovascular invasion (15% vs. 25%), lobular (10% vs 18%) and grade 3 cancers (20% vs 34.1%) albeit not significant. ER status (80% vs 79.6%) and postmenopausal age (90% vs 88.6%) were similar. Conclusion Axilla management of patients with pre-operatively diagnosed lymph node metastasis currently leads to overtreatment in 31.3%. There is scope to identify patients with a low nodal burden to select them for axillary staging and possibly avoid ALNC.
PB.9
The use of nomograms to predict additional lymph node metastasis after Sentinel lymph node biopsy: Can they reliably identify those needing no further axillary treatment? Sophie Greenhalgh 
Introduction
Invasive lobular cancer (ILC) attributes to 5-10% of new breast cancer diagnosis. It is often mammographically occult with detection rates of 57-87%. Fibroglandular tissue density is inversely correlated to mammographic detection rates and there is also an increased rate of multifocality in ILC. MRI has higher detection rates of 93% and is recommended in patients with ILC. Theoretically mammographic ILC detection should be better in fatty breasts and therefore we ask whether MRI essential in this subgroup of patients? Aim To ascertain if MRI detects any significant additional lesions in patients with ILC and fatty breasts. Methods Retrospective study of breast MRIs conducted within a 4 year period for histological confirmed ILC. Breast densities of 1 were included. All imaging reports recorded. Results 134 patients identified with ILC, 103 excluded as had breast density 2 or more. 31 identified as having breast density of 1. Primary lesion identified on mammography in 28 patients and on ultrasound in 3 patients. MRI identified additional findings in 9 patients which were occult on mammography. Of these 9 cases, 3 were identified as additional cancers and the remaining 6 were benign. Conclusion MRI detected 3 additional cancers which were otherwise occult on mammogram despite the patient having fatty breasts. These results are congruent with published literature. A study published in 2012 identified 7 additional cancers in 32 cases. We therefore conclude that MRI is necessary in imaging patients with ILC and low density breast tissue on mammography. Results Total of 27% scans had relevant findings which required further investigations. Benign lesions contributed 20% to the relevant findings, 5% of these required change in management. Sinister findings were depicted in 80% of all the relevant findings. Metastases contributed 30% to the relevant findings. In terms of disease extent or localisation identified with high clinical suspicion and negative imaging, 20% had mammographically occult carcinomas, multifocal disease was present in 20%, 1/20 had diffuse disease and 1/20 was positive for contralateral carcinoma. In summary, management was changed in 23.2% of all the scans.
Conclusion
Breast MRI does demonstrate significant additional lesions. Though these warrant further imaging, patient management and MDM recommendation may alter which is proven in 23.2% of cases in our study. is used to monitor tumour response to neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC) through analysis of tumour morphology (size and shape) and contrast kinetic patterns. This study aimed to identify pre-NAC MRI and tumour features which could help predict response to NAC. We also investigated the ability of post-NAC MRI to accurately represent the extent of any residual disease which is of importance for surgical planning. Methods This retrospective cohort study evaluated forty-six patients with LABC who received NAC between 2008 and 2016 at UHCW. All patients underwent pre and post-NAC DCE-MRI and proceeded to surgical excision. Clinical and imaging data was collected from CRRS and UHCW PACS. Results Several tumour features were found to be predictive of pathological response, including: tumour morphology, oedema, shrinkage pattern, HR status, HER2 status and percentage change in MRI long diameter. Circumscribed lesions were more likely respond to NAC than irregular, diffuse and nodular tumours. There was some evidence of correlation between MRI morphological categories and tumour receptor status. The accuracy of post-NAC MRI for predicting residual disease was superior for HR negative tumours. Conclusions Pre-treatment MRI features can serve as reliable imaging biomarkers which can be used to predict disease response to NAC. The accuracy of post-NAC MRI varies with tumour biology and imaging features, and this should be considered in decisions about surgical approach.
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Comparison of digital mammography, ultrasound and MRI in the preoperative size assessment of lobular breast cancer: A district general hospital experience Sachin Kamat Introduction Tumour size assessment with imaging has an impact on the diagnosis and treatment planning of breast malignancy. We assessed the correlation between preoperative size of lobular breast cancer on different imaging modalities and postoperative histological size, as the reference standard. Methods Retrospective review of lesion size on digital mammography (DM), ultrasound (US) and contrast-enhanced MRI from 73 breast lesions was performed in 63 consecutive women with histological diagnosis of lobular breast cancer. The sizes of different modalities were correlated with histological tumour size using paired T-test analysis and coefficient of determination.
Results
Of the 63 women included, 3 (5%) had bilateral lesions and 7 (11%) had 2 foci in the same breast; 73 separate lesions were entered in the analysis. Of those who went to Mastectomy 7 had 2nd look Ultrasound and biopsy (1 contralateral breast) and 2 had 2nd look ultrasound and no biopsy. Conclusion 17% of our cases had MRI showing that we are adhering to the NICE standard. In 60% of cases MRI allowed for successful single conservative operation. MRI allows picturisation of tumour morphology e.g. 2 discrete lesions or 2 lesions with extensive disease between them, aiding appropriate surgery. MRI needs to be reported by expert breast radiologists and interpreted within the clinical context by the MDT team. Aim Both performing and reporting breast MRI scans is time consuming and expensive. An alternate method for imaging and reporting which achieved excellent results utilising a shortened protocol and rapid reporting was reported by C. Khul et al. This retrospective study was used to test the feasibility of such protocol in a centre which is starting to perform high risk breast MRI screening. Methods Three consultant radiologists (C1, C2 and C3 with 7 to 9 years of experience in reading breast MRI) retrospectively and independently reviewed 27 high risk breast MRI studies. All cases were annonymised and review was only performed as per C. Khul's paper, that is MIP images and abbreviated protocol images consisting of pre-contrast, first post-contrast and its subtracted counterpart were only reviewed and reported. Time taken for MIP and abbreviated protocol reading and the sensitivity and specificity for both were calculated for each reader. Results Average time to read MIP and abbreviated protocol images were: C1 = 1.8 and 26.3 sec, C2 = 2.6 and 8.1 sec and C3 = 5.3 and 63.7 sec. Only one patient had cancer (bilateral cancer) and imaging finding were scored R3 and R4 for right and R5 for left by all readers. Therefore, no cancer was missed. Altogether 7 cases underwent 2 nd look US and found to have benign results. Conclusion This small study shows that the method reported by C. Khul is feasible and should result in lower cost service. Prospective larger scale UK study should be considered.
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Characterisation of cancers from digital mammograms from a large scale database: size, conspicuity and appearance Alistair 
Introduction
There is a lack of collated data on the appearance of cancers in digital mammograms. This information may help in understanding which lesions appearing in mammograms are potentially fatal and which low risk. Methods Mammograms have been collected since March 2011 from three breast screening sites alongside the clinical information from National Breast Screening Service (NBSS). Experienced readers have marked a rectangular region of interest (ROI) closely around identified cancers and classified each cancer's conspicuity and appearance. The cancers size was calculated as maximum dimension (height or width) of the ROI. The data were analysed to investigate the appearance of the cancers. Results Currently, there are 4657 women's images in the database with invasive and in-situ cancers. 3400 of the cancers have been marked with complete data. Most of the cancers were described with an obvious conspicuity (67%) rather than subtle or very subtle. It was found that 10%, 22%, 21%, and 47% of the cancers were in the following mammographic size ranges ≤10mm, 10-15mm, 15-20mm, >20mm respectively. The most common cancer appearance was masses (50%), followed by calcification clusters (28%), asymmetric densities (13%) and architectural distortions (9%). The masses were classified as illdefined (58%), spiculated (38%) and well defined (4%), also 14% of them had associated calcifications.
Conclusion
We have characterised the appearance of a large set of cancers.
Once the database is fully linked to data in NBSS, then cancer grade and biology can be included in the analysis. Objectives Undertake a systematic review comparing CESM with FFDM, to establish whether sensitivity and specificity of breast cancer detection is significantly improved. Methods A comprehensive search of journal databases and grey literature sources was performed using multiple terms for CESM, FFDM and breast cancer to identify relevant literature. These studies were screened against pre-determined inclusion and exclusion criteria to ensure they were applicable to the review question. The included studies were quality assessed and their data extracted.
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Results
Eleven relevant studies were identified. These performed the same CESM technology (G.E. SenoBright®) and varied mammography technologies on the same patients with either newly diagnosed breast cancer or suspicious imaging. All studies showed CESM increased sensitivity by 3.1-21.2% and 10 studies showed increased specificity by 5-45.7% (one study found specificity decreased by 4%) compared to mammography. However the differences were not always significant, the data was heterogeneous, and none of the included studies fully demonstrated low risk of bias when quality assessed. Conclusion CESM may improve sensitivity and specificity of breast cancer detection compared to mammography. However further research is required to establish applications and determine which patients would benefit.
Introduction
To analyse the pattern of parenchymal tissue on mammography in women with the densest breasts, variation with age and the effect on recall rates and cancer detection. 
Approximately 10% of symptomatic female breast cancers (BC) are mammographically occult (MO) yet data is scarce regarding presentation and histology of the primary and any recurrence. It is unknown whether mammographic follow-up is appropriate. We are auditing women diagnosed with symptomatic MOBC across 3 UK centres, to increase the knowledge base and inform future surveillance methods. We present preliminary results. Method For each centre women ≥ 35 attending as GP referred between 2006 and 2010, undergoing mammograms and diagnosed with a symptomatic MOBC were retrospectively identified. Presentation, histology and treatment data was collected. Type/frequency of imaging followup and subsequent recurrences to 31.12.15 were documented. Each MOBC identified was age matched with 2 women with a mammography visible cancer. Results 116 MOBC were identified across 2 centres (332 controls), average age 53yrs. 76.5% presented with a lump vs 81.6% in the control group. 37.3% vs 17.5% had very dense parenchyma. Mean size at diagnosis was 15.5mm (range 4-37) vs 24.0mm (range 4-90). 11.1% vs 9% were lobular. 62.6% vs 51% were node negative 91.1% vs 90.3% were ER+ve and 11.2% vs 20% were HER 2+ve. 52.4% vs 33.4% underwent breast conservation. Mammographic follow up was similar for each group; median 5.4yrs (range 0.4-9.9). All 6 recurrences to date were visible on mammography. Conclusion Preliminary data suggests that MOSCs are more common in dense breasts, but smaller at diagnosis favouring surgical conservation. Recurrences are not necessarily occult so mammographic follow-up may be appropriate. Further data is being collated to consolidate findings. . The use of HRT showed an expected positive correlation with FGV.
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Conclusion
There was an overall decrease in MD over the 3-year period. However, 48.7% of women demonstrated an increase in MD; in particular women with normal BMI, postmenopausal women and women on HRT. These data show that to fully understand changes in individual MD for both breast cancer risk prediction and risk reducing interventions, confounding factors must be taken into account.
Introduction
Breast screening in the UK is undergoing many workforce changes as more experienced radiologists retire and new readers become engaged. With such major changes it is important to monitor mammographic interpretation skills for national quality assurance purposes. A detailed analysis has been carried out to compare the performance of 'newcomers' to the national performance measures on the PER-FORMS scheme of more experienced readers. Methods All UK screening readers take part annually in the PERFORMs educational scheme. 59 new participants read a recent set of PERFORMS cases. Nationally, 726 more experienced readers also read the difficult same cases. Results A two-tailed t-test indicated that the mean of cancer detection of new participants was significantly lower as compared to the national average of more experienced participants (p<0.0001, M new =72.35% M national =85.82%). The correct recall (sensitivity) of the new participants was also significantly lower than the national average (p<.000001, M new =72.88%, M national =85.92%). Additionally, the correct return to screening (specificity) of the new participants was significantly lower than the national average (p<.000001, M new =85.86%, M national =83.55%). Conclusions On several performance measures, new breast screening readers performed significantly worse than more experienced readers. This may partly be due to them being new to taking part in the PERFORMS scheme but that cannot fully explain the very significant differences found. The purpose for the PERFORMS scheme is to highlight such performance differences and to then help new, and poor performers, improve and maintain their performance so that the quality of the National Screening Programme remains high despite workforce changes.
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Introduction CESM produces low and high energy images at specific time intervals taken once a patient has been injected with an IV contrast agent. In the post processing phase the two images are recombined producing an image in which contrast enhancement is visible. Studies show it to be as sensitive as MRI in detecting uni and multi focal disease, potentially providing an alternative to MRI for specific patient groups. Methods A single centre matched study comparing the sensitivity and specificity of CESM with breast MRI of patients who had both CESM and MRI performed within the trust was conducted. Images were reviewed and the following data extracted: Number of lesions Lesion size Histology results -grading and size Data was analysed; sensitivity, specificity, PPV and NPV of CESM verses MRI were calculated. Results A total of 31 women participated in the study. Results show that CESM had a sensitivity of 97% (36/37) and a specificity of 60% (3/5) with a PPV of 94% (36/38) and a NPV of 75% (4/5). MRI had a sensitivity of 100% (38/38) and a specificity of 75% (3/4) with a PPV of 97% and a NPV of 100%. Conclusion Results show the sensitivity and specificity of CESM is similar to that of MRI. Preliminary findings show, in specific cases CESM could be used as an alternative to MRI in lesion detection. As this is a small sample size, further analyses of future data should be performed to see if changes to practice can be implemented.
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Image versus imaging: Do breast implants compromise cancer detection at screening? Steven Henderson 1,2 , Janet Litherland
Introduction
There is ongoing concern that silicone implants, particularly those placed in a subglandular position, may reduce the sensitivity of mammography in the detection of malignant lesions. Our aim was to determine whether or not breast implants affected the cancer detection rate in our screening population. Methods A retrospective search was undertaken to identify all patients with breast implants who had been diagnosed with breast malignancy, through the West of Scotland Breast Screening Programme (WOSBSP), over a period from April 2010 -March 2015. The number of malignancies was then compared with the number detected in the non-implant population during the same time period. Results During the period, 310,558 patients attended for screening. Of these, 852 had breast implants. A total of 2,840 malignancies were detected, 6 of which were in patients with implants -1 prevalent and 5 incident. All 6 had subglandular implants. There were 3 diagnoses of DCIS and 3 of invasive carcinoma, with a size range of 10-34mm. None of the patients had nodal disease at the time of diagnosis. The malignancy detection rate in the implant group was 7 per 1000 and 9.2 per 1000 in the non-implant group (P=0.52).
Conclusion
Although there appears to be a trend towards a lower cancer detection rate in women with implants, the results do not reach statistical significance. However our study is limited by small numbers of cancers in women with implants and this also precludes further analysis of data for invasive and small cancer detection rates.
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Correlation Imaging of breast implants is increasingly performed to investigate suspected leak or rupture. However, there is little opportunity for the radiological findings to be correlated with the pathological findings, providing feedback as to the accuracy of the radiological diagnosis. We reviewed pathological findings in explanted breast implants, in conjunction with the radiological findings, to investigate the accuracy of imaging for breast implant changes. The pathology database was searched for all breast implants removed between July 2000 and January 2015. All patients identified had their imaging history reviewed to identify those with pre-operative imaging. Pathological findings at implant removal and radiological findings on the pre-operative imaging were compared. There were 106 implant related pathology cases identified. From this, 11 patients had explant of breast implants and pre-operative imaging. In 8 cases implants had been placed for cosmetic augmentation, 3 were following implant-based reconstruction. 10 cases had pre operative ultrasound, 1 had MRI and 1 had both. Radiological findings demonstrated intra or extra capsular rupture in 9, silicone granulomas in 1 and an intact implant in 1 case. Imaging findings were consistent with the pathological findings in all cases.
Imaging of implants provides an accurate pre-operative assessment of implant pathology. As many more implants are imaged than removed, and many implants removed without any pre operative imaging, it is difficult to get feedback about the accuracy of radiological diagnoses in this setting. Although small, this study shows 100% concordance between radiological and pathological findings following the pre-operative imaging of implant pathology.
Introduction
Patient's symptoms and clinical examination are useful but can be non-specific for breast implant rupture. We wanted to determine in our unit how the presenting clinical features correlated with implant rupture diagnosed on MRI. Lobular neoplasia in situ is classified as a B3 lesion of uncertain malignant potential and confers an increased risk of concurrent and future malignancy. In the absence of national guidance there is uncertainty over optimal management and peak malignancy risk may not fall within the 5 years of annual surveillance recommended by some centres. Biopsy reports from 1999-2015 at Southampton General Hospital were screened for code B3 and/or diagnosis of LNIS with collection of a comparison group of patients with B2 diagnoses. Recommended management was noted and screening packets were reviewed to identify subsequent assessments and biopsies. LNIS was diagnosed in 130/12,141 breast biopsies (1.07%) performed between 1999-2015 Concurrent malignancy was present in 44/130 (34.68%) of which 33/44 were infiltrative lobular cancer and a further 7/130 (0.05%) had a B4 or B5a diagnosis. Management of pure B3 lesions was highly varied in those with available follow-up data (58/ 130) but most commonly comprised routine recall following surgical excision biopsy (34.5%). Women with a B3 diagnosis of LNIS were at increased risk of developing invasive malignancy compared to the B2 group (8.62% and 3.13% respectively, p=0.21) and the average time to malignancy was 15 years. The high rate of concurrent malignancy, in particular invasive lobular cancer, may support the theory that LCIS is a precursor lesion. LCIS also confers an increased risk of subsequent invasive neoplasia which in this study occurred on average 15 years from LCIS diagnosis. This timeframe should be considered when recommending management with enhanced mammographic surveillance.
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The changing risk factor profile of Asian women with breast cancer Method 321 Asian patients diagnosed with breast cancer at the Nightingale Centre and Genesis Prevention Centre, University Hospital South Manchester between 1999 to 2016 were divided into 6 year groups according to their year of diagnosis. Established breast cancer risk factors were analysed across the three groups to identify potential changes and trends. Statistical analysis was performed across these three groups primarily using analysis of variance (ANOVA) for continuous variables and Pearson's chi-squared tests for categorical variables.
Results
There was a decreasing trend of proportion of patients with diabetes mellitus (p<0.001). There were increasing trends for mean age of first full term pregnancy, mean duration of interval between menarche and first full term pregnancy, proportion of women who breastfeed, and BMI. There was a decreasing trend of proportion of multiparous women. However these findings were statistically insignificant. Conclusions There are changing trends in certain risk factors for breast cancer which might contribute to the increasing incidence of breast cancer in Asian women. More research has to be done on modifiable breast cancer risk factors and how they can be altered to decrease breast cancer risk. A survey of radiographer film reader's perceptions of workload, performance and job satisfaction in the NHSBSP. Introduction Age extension has increased the film reading workload in breast screening. A reported shortage of radiologists plus radiographers double reporting also has the potential to increase reading volumes. There is disagreement on whether performance declines with increasing volumes. There are no recommendations on maximum reporting volumes. This survey aims to identify themes which affect film readers' perceptions of workload, performance and job satisfaction. Methods Purposeful sampling was used to select participants. All qualified radiographer film readers were included. Electronic questionnaires were distributed to managers to forward to participants. Thematic analysis was used to analyse results. Results The overall response rate was 37%. 77% perceived an increased workload. 60% report a sufficient workforce for reporting. 40% report high volumes. Performance is thought to fluctuate following interruptions, PERFORMS and fatigue. 84% are satisfied in their role. Conclusion Radiographers are experiencing an increase in workload but reporting time is frequently interrupted. Audit should assess any effect on performance by high volumes and visual fatigue. More time for CPD is required and increased involvement in research and audit. Job satisfaction is high amongst readers which should aid retention and recruitment. With a potential future shortfall in radiologists, the NHSBSP will be reliant on advanced and consultant practitioners to maintain targets. There is the potential to further develop the role but care should be taken not to compromise performance and job satisfaction with the volume of work.
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Introduction
The NHSBSP KPIs require 90% of first offered appointment (FOA) and first actual assessment (AA) to be within 21 days of screening mammography. This leaves little flexibility for women unable to attend FOA. Our unit consistently achieves FOA (monthly rates 93%-100% in last round), but frequently breaches the AA (monthly rates 78%-100%). We investigated why the breaches occur. Methods NBSS data were analysed for women recalled from screening for the 3 years spanning April 2013-March 2016. Results Of 3595 women recalled to assessment, 99.6% of FOA were within the required timescale. Of these, 464 women were not able to make their FOA. 113 women made an alternative appointment and attended assessment within the 21 day limit; the remaining 351 did not. Overall, 377 (10.5%) of recalled women failed to have their AA within 21 days, with seasonal variation observed. In just 3.7% of all breaches was the unit unable to make a FOA within 21 days. A further 5.0% comprised a data entry error on NBSS, erroneously registering as a breach. Of the remaining breaches, 76.7% changed appointment at least once; 14.6% failed to attend FOA (DNA) without contacting the unit; 1.1% had a DNA and made at least one other appointment change. Reasons women changed appointments: inconvenient 55.0%; on holiday 37.4%; unwell 3.1%; combination of these 4.5%. Conclusion Time to actual assessment frequently reflects client choice and/or circumstances. These factors are outside the control of the unit, making the time to actual assessment a questionable measure of performance. Patients are advised to report any breast associated symptoms during their screening mammograms in the Warwickshire, Solihull and Coventry Breast Screening Service (based at UHCW NHS trust). Although no specific guidance on whom to recall exists, symptoms such as lump, distortion/change in shape of breast, recent nipple discharge, eczema, or recent inversion, skin tethering and dimpling are routinely recalled for further assessment. In this retrospective study, we investigated the types of symptoms reported and subsequent clinical, imaging and histology findings with specific aim of finding the number of cancers in this cohort of patients. Between 2011 -2015 data was collected from NBBS and hospital RIS, PACS and CRRS on patients reporting symptoms during their routine screening mammogram. This included 709 patients (age range: 47 to77 years, mean age of 56 years). Subsequently, 15 patients were diagnosed with breast cancer, of these 3 patients were excluded as 2 of them were originally referred by the radiographers who noticed the changes at the time of screening and the third patient would have been recalled anyway for abnormal mammography. Among the remaining 12 patients, 6 had cancer on a site or side completely different from the actual location of symptom patient identified. Therefore, 6 out of 709 patients (0.84%) who were recalled were concordant with clinical symptoms. This study shows the positive predictive value (PPV) of patients who reported symptoms turning into a breast cancer is low. Therefore, an alternate pathway of managing these patients should be investigated.
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The association between regional disposable household income and uptake of breast screening in England between 1999 and Aim To examine possible associations between regional disposable household income and uptake of breast screening and investigate whether any association is related to the type of invitation, categorized as: first invitation; invitation to previous non-attender; invitation to previous attender (last attendance <5 years); invitation to previous attender (last attendance >5 years) and early recall invitation. Methods Data on breast screening uptake and Gross Disposable Household Income (GDHI) per head for the English regions for the years 1999-2014 were obtained from the Health and Social Care Information Centre and the Office for National Statistics respectively. Uptake data were adjusted to fit calendar year and GDHI data were adjusted for inflation. The association between these was assessed using multiple linear regression. Results There was a significant (p<0.05) positive association between regional GDHI per head and overall breast screening uptake with a coefficient of 0.00066 (95% confidence intervals 0.00027-0.00106). This is equivalent to a 0.66% rise in breast screening uptake for every £1000 increase in regional GDHI per head. No type of invitation alone showed a statistically significant association between GDHI per head and breast screening uptake. Conclusion Regional disposable household income has a positive association with uptake of breast screening in the English regions. In this study, there was no significant association between GDHI per head and breast screening uptake for any one type of invitation. Low income populations should be targeted to reduce inequalities and further research should determine which interventions can be cost effectively applied to these populations.
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Is double reading still a requirement in the NHSBSP in the digital era? Liz Edwards 
Background
The South Asian population has increased across the UK along with increase in breast cancer incidence in them. Yet the uptake rate for breast screening in this group of women remains significantly lower. Barriers to screening, such as language barriers can deter some women from attending. Materials and Methods A pilot questionnaire study was carried out to assess the screening experience of 110 women who watched a breast screening video on a tablet device in their choice of language prior to screening. The screening experience was assessed by a five item questionnaire. For advanced understanding of the device and its related issues, supplementary data was collected in the form of a radiographers' feedback questionnaire (n=92).
Results
The majority of the women participating were supportive towards this method of help (85%) and had favourable opinion about the device (90%). In total 93% of the women agreed that the video helped them through the mammography procedure and 79.2% agreed that it made their screening experience better. The radiographers' feedback suggested that time was a sensitive issue in applying this method, with 39% suggesting it increased the clinic times.
Conclusion
The usage of multilingual tablet device was perceived positively by the majority of women attending for breast screening. It was considered helpful in improving the individual's screening experience and possibly will have a positive impact on their compliance in subsequent screening rounds. The tablet device should be considered for national piloting as part of the National Breast Screening Programme. Results 57 patients were booked for an MRI guided intervention (31 Royal Marsden patients, 26 external referrals). The appointment for biopsy was on average 14.5 days after the MDT decision. The average procedure duration was 89 minutes. No enhancing abnormality was demonstrated on procedural MRI in six cases, other technical reasons preventing successful biopsy included posterior positioning of the lesion (n=1) and software failure (n=1, successfully repeated). Of 47 biopsies performed, histology showed 15(32%) B4/B5a/B5b, 4(9%) B3 and 28(60%) B1/B2. In situ disease more commonly demonstrated non-mass like enhancement (3/4) whereas invasive disease usually demonstrated mass features (9/10). There were 4 'significant bleeds' requiring monitoring in the department and one vasovagal collapse which necessitated repeat procedure. Conclusions Our cancer detection rate (32%) is comparable to other UK centres 1 and higher than studies in Europe (21%) and USA (8%) 2,3 , suggesting appropriate case choice. Technical difficulties and complications were part of the learning curve, and practices have evolved to minimize these. 
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Initial single centre experience with the Intact TM percutaneous breast lesion excision system (Intact) using Ultrasound (USS)Introduction Intact is a breast biopsy device that excises a breast abnormality using vacuum and radiofrequency (RF) technology. It is licenced in UK as a mammographic-mounted device, or a hand held device for USS guidance. Research from USA showed complete removal of breast abnormalities occurs frequently during Intact breast biopsy but experience in UK is limited. We present our centre's initial experience using Intact under USS guidance. Methods Selection of masses for Intact depended upon the size of mass and the willingness of the patient to undergo the procedure, initially under general anaesthesia (GA) immediately prior to her therapeutic excision, and subsequently under local anaesthetic (LA). For the local anaesthetic cases an additional criteria for U5 masses was that surgical excision under general anaesthetic was contraindicated for the patient due to co-morbidity.
Results
19 selected breast masses in 15 women were biopsied under USS guidance using "Intact".
GA: 11 masses in 9 women (January 2012-July 2013). LA: 8 masses in 6 women (September 2015-July 2016). Histology included B2 (8), B3 (4) and B5 (7) masses. Sizes for B3 and B5 masses: 4-17mm. 6/7 B5 and 4/4 B3 masses -histology confirmed complete excision with Intact.
No complications from the Intact procedures.
Conclusion
Our initial experience suggests it is safe to perform Intact under LA and USS guidance in an outpatient setting and that Intact offers the potential to avoid subsequent excisional surgery for small B3 and carefully selected small B5 masses in the future. Purpose/background/objectives Vacuum assisted breast biopsy (VABB) is a minimally-invasive modality enabling target lesions identified within breast tissue to be either sampled or removed. A biopsy needle is advanced percutaneously to the target under stereotactic, ultrasound or MRI guidance, whence multiple samples are harvested. This pilot survey explored whether differences in acute and persistent pain intensity occurred between ultrasound and stereotactic-guided VABBs. Methods A questionnaire-based survey was undertaken; basic demographic and procedural data for patients was recorded at the time of VABB. Participants completed a pain/analgesia diary detailing the intensity of pain experienced and analgesia taken over the 7 day post-VABB period. Participants were contacted at 3 months post-VABB to determine the presence of persistent pain. Results 49 participants were recruited and 38 completed questionnaires were returned (27 US, 11 stereo'). Statistically significant differences were observed in the intensity of pain experienced post-biopsy by patients who underwent US and stereo VABB on day 1; 3.4 (SD 2.8) vs 1.4 (SD 1.6) P=0.04, day 4; 1.3 (SD1.5) vs 0.2 (SD 0.6) P=0.03, day 6; 0.7 (SD 0.9) vs 0 P=0.03 and day 7; 0.7 (SD 1.0) vs 0 P=0.03. No procedural differences existed between the groups. 3 patients (8%) reported persistent pain at the 3-month time point, all had undergone USguided VABB. Conclusions Patients undergoing US guided VABB experienced more intense pain in the week following biopsy than those undergoing sterotactic guided VABB and appeared to experience more persistent pain. Further work is required to determine the cause of these findings.
Aim
Largest series comparing the unit current standard-of-care, Pronestereo(PS) Vacuum Breast Biopsy(VAB) with Digital Breast Tomosynthesis (DBT)-guided VAB. Background DBT is an established mammographic technique shown to improve the accuracy of soft tissue lesion characterisation, conspicuity and cancer detection. VAB increases the sensitivity of pre-operative diagnosis, reducing upgrade rates. Method 170 consecutive patients through the NHSBSP and symptomatic breast service undergoing stereo-guided biopsy were recruited into 2 arms: Multicare-Platinum-Prone-Stereotactic-Breast-Biopsy-System Affirm-Breast-Biopsy-Guidance-System with 3D Breast Biopsy using Hologic Selenia Dimensions VAB was performed using the Atec-Sapphire with 9G Eviva needles. Procedure outcomes including patient comfort, time, accuracy, radiation dose and complications were recorded. 
Conclusion
We demonstrate DBT-guided biopsy is a good alternative technique to stereo-guided biopsy for soft tissue abnormalities (including those occult on 2D and ultrasound) and microcalcifications. There is an increased risk of vasovagal episodes with upright DBT, which could be avoided with decubitus positioning or Prone-DBT.
Introduction
The management of B3 lesions is becoming increasingly under debate in light of criticism of over-diagnosis within breast screening. New proposed guidelines throughout the UK are suggesting that surgical biopsy for many B3 lesions may no longer be required. In this audit we review all cases of B3 at initial biopsy over two fiveyear cohorts. Methods Data was collected using the National Breast Screening System. 208 14G core biopsies and 256 initial vacuum biopsies were performed. 50% of patients in the first cohort underwent benign surgical biopsy compared to 40.4% in the latter cohort. There was a 6% upgrade to invasive malignancy and 18% upgrade to non-invasive malignancy over the 10-year period following surgical biopsy and vacuum excisions. The upgrade rates for each histological category were:
Atypical duct hyperplasia 36% Flat epithelial atypia 28% Radial scar/complex sclerosing lesion with atypia 27% and with no atypia 11% Papilloma with atypia 55% and with no atypia 16% Lobular neoplasia in situ 43% Suspected phyllodes tumours 8% Atypical apocrine adenosis 20%.
Conclusions
The results of this audit and upgrade rates are in line with the literature. Upgrade rates remain high even with first line use of vacuum biopsy. Careful consideration is essential prior to changing current practice.
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Prospective follow up of patients with B3 lesions over a 4-year period Naveed Altaf, Nerys Forester RVI, Newcastle, UK Correspondence: Naveed Altaf Breast Cancer Research 2016, 18(Suppl 1):PB.48
Following introduction of large-bore vacuum-assisted biopsy (LVB) for diagnosis and management of B3 lesions in 2011, a prospective database of patients was developed. Following B3 lesion diagnosis on core biopsy, patients underwent LVB. If B5, patients had surgery; if B3 patients underwent 5 years annual surveillance mammography (ASM) or were discharged/returned to routine recall, depending on the presence of epithelial atypia. Outcomes were prospectively audited over 4 years. B3 lesion database analysed to ascertain number of ASMs performed, recall rate, symptomatic episodes and subsequent malignancy following B3 diagnosis. Between October 2011 and December 2015, 396 patients had a B3 lesion. 305 underwent second line LVB. 27 patients diagnosed with malignancy following LVB and 17 patients were upgraded to malignancy following excision biopsy (unsuitable for LVB/pathology request). 352 patients had ASM/routine recall, together having 410 mammograms performed over 4 years. 9 patients were recalled from ASM (recall rate 2%). 20 underwent further breast investigations (19 presented symptomatically, 1 recalled from MRI high-risk surveillance). From additional investigations 3 cancers diagnosed (1 following high-risk surveillance MRI; 1 symptomatic presentation, 1 recall from ASM). There were also 4 further B3 lesions and 22 benign diagnoses. LVB for B3 lesions is an excellent alternative to excision biopsy. However, ASM has a low recall rate and cancer detection rate, with only 1 of the 3 subsequent cancers detected by mammographic surveillance. This questions whether ASM is really necessary in this group of patients. Could they be safely returned to routine recall within the screening program?
Introduction IBC is an extremely aggressive breast cancer with a very poor prognosis. Routine imaging includes staging CT and bone scan. PET CT is considered superior to CT. We reviewed cases of IBC in Leeds from [2008] [2009] [2010] [2011] [2012] [2013] [2014] Of the initial 19 negative staging CT scans, 1 patient died of an unrelated condition. 9/18 (50%) developed metastatic disease at follow up (6months-5years). Of the indeterminate CTs, 2/5 (40%) went on to develop metastases at 2 months and 2 years respectively. Conclusion Metastatic disease is common in women presenting with IBC and accurate staging is essential in guiding management and providing prognostic information to patients. 70% of our cohort had an initial staging CT, when all patients should be undergoing this. Of those who received an initial negative staging scan, 32% of these had metastatic disease within 12 months. In view of this, a PET/CT is the recommended staging modality of choice to allow for more accurate staging in this cohort,enabling better management in this select group of patients.
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The Borderline breast lesions (B3 lesions) can coexist with malignancy. The magnitude of this risk varies between studies and lesion subtypes. This systematic review of the literature will determine an accurate estimate of the risk of invasive/in-situ malignancy identified by surgical excision biopsy, following diagnosis of a B3 lesion at core biopsy, within each B3 lesion subtype, to guide risk stratification and improve management strategies. Literature searches (MEDLINE, Embase, HMIC, Scopus and Web of Knowledge), identified relevant studies between 1980 and 2014. Literature appraisal, meta-analysis and subgroup analysis performed to determine malignancy risk for all subgroups of B3 lesions (Papilloma, Radial Scar, AIDP, Lobular Neoplasia and FEA). Searches returned 2289 citations, with 11 identified from other sources. Duplicate, unsuitable articles and abstracts/posters/reviews were excluded leaving 183 records. From these, 54 full text articles did not meet inclusion criteria. Meta-analysis was performed from 129 studies. Rates of malignancy varied from 6% in a radial scar with no atypia, to 32% for a papilloma with atypia. Differences in malignancy upgrade rates between atypical and non-atypical lesions were statistically significant (p<0.05). Study heterogeneity could not be explained by differences in core biopsy size or year of publication, however, a significant difference in upgrade rates to malignancy was observed between the US and non US literature. Many studies have assessed the risk of malignancy following diagnosis of B3 lesions, but are often small and lack statistical power. This study is a comprehensive, inclusive assessment of the available literature, on which to base tailored management strategies.
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The use of supplemental imaging in post-surgical follow-up of women with breast cancer Anthony Maxwell Introduction With increasing breast cancer incidence and improved survival, optimised follow-up strategies are required to maximise quality and duration of life. Whilst periodic mammography is adequate for most older women, its sensitivity in younger women and those with dense breasts is poor. Recurrences or new primaries in women whose original cancers were mammographically occult may also be occult. This study investigates the use of supplemental follow-up imaging in these groups. Methods An on-line survey of members of the British Society of Breast Radiology was performed, enquiring about the use of supplemental imaging follow-up, indications, modalities and numbers of women. One response only per hospital was requested. Categorical responses were reclassified where appropriate in line with submitted comments.
Results
Thirty-four valid responses from UK centres were received. Half treat >400 women with new breast cancers per year. Screen detected cancers comprise <25% of cases in 15% of centres and 25-75% in 85%. Additional imaging (mostly MRI) is offered by protocol/ad hoc in 0 and 8 (24%) units respectively for those with dense breasts, in 2 (6%) and 10 (29%) units for young women, and in 5 (15%) and 17 (50%) units for women with occult original cancers. Most perform <20 supplemental examinations per year. Local professional consensus and patient requests were the main reasons for providing additional imaging. Introduction Our aim was to audit the referral of male patients to our unit, where all males, are imaged. For the purposes of this study, we used the following criteria to justify imaging: i) Unilateral gynaecomastia (P2), >40 years ii) P3-P5 or equivalent clinical description, any age
Conclusion
Methods
Retrospective review of all referrals for male breast imaging, over a 30-month period, from 01.01.14-30.06.16. We recorded the referral source, clinical details including patient age, presenting symptoms and P value, imaging findings, and histological outcome.
Results
Over the 30-months, 518 males imaged. An increase in referral over this period amounting to >50% per annum. Referral source: 322/518(62%) from breast surgery, 181/518(35%) GP and 15/518(3%) from other specialties. Age: 13 to 93 years, bimodal peaks: 22-30 and 67-75years. 480/518 (92%) patients with P1/P2/clinically benign and U1/U2 and no biopsy. 4 patients, all >40 years, were P2U3B2. 20/518 (4%) patients biopsied -due to either clinical or imaging concerns. 1xB3 (in a P3U4 patient; no upgrade on sequent surgical excision) and 14 benign conditions (all U2/U3). Remaining 18/518 patients, all P3U1/U2, were clinically reviewed +/-clinical core. All clinical cores were benign. 5/518 (1%) patients, all >70 years, all with P4/P5/clinically suspicious andU3-U5. Biopsy yielded malignancy: 4xB5b and 1xmelanoma. 30% justification rate according to audit standard criteria. Conclusion Multisource referral, increasing numbers and a cancer detection rate <1% in a department where all males are imaged. All clinically benign cases proved benign. All cancers were suspected. Findings strongly support the formulation of local guidelines. A high percentage (68%) of incidental lesions were malignant. We propose to develop a radiology:breast radiology referral pathway to address both these issues and improve standards of care for these patients at increased risk.
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Introduction
Male breast cancer is rare affecting < 1% of the male population. We have observed a marked growth in the number of men referred for imaging and propose that imaging of all men may not be necessary.
Method
Retrospective review of all men referred for imaging between 2010 -2015. Clinical history, imaging and pathology were reviewed. Results Total of 452 patients. 3 patients were referred for imaging in 2010 compared with 162 in 2015. In total, 11 patients were diagnosed with breast cancer, 2 with metastases from another primary and 3 with lymphoma. Of these 16 patients, 2 were not given a numerical P value but the clinical history stated suspicious mass. 12 (75%) had a P value of P3-P5. 2 patients were clinically P2 but both had significant history: 1 of blood stained nipple discharge and the other of previous renal cell carcinoma. The average age of the 16 patients was 75 years, the youngest 53 years. In 2015, 84 (52%) patients referred for imaging were clinically graded P2 gynaecomastia confirmed on ultrasound alone (U2). 10 patients were clinically P2 gynaecomastia, ultrasound was indeterminate (U3) but core biopsy confirmed gynaecomastia. The incidence of malignancy was 3%. To establish if the number of M3 reports have increased or decreased and to quantify the positive predictive value of M3 reports. Methods DBT mammographic reports over 12months were reviewed and compared with FFDM reports in the previous 12month period, evaluating 'M3' reports and their subsequent up-or downgrading. Cases were evaluated to identify the following -additional mammographic views, ultrasound grading, histopathological classification and final diagnosis. Results There were less M3 reports overall. Of the M3 reports, more were true positive than in the previous year. Within this specific cohort we identified a 10.10% increased likelihood of ultrasound upgrade following DBT compared with FFDM, a 25.7% increased likelihood of histological upgrade and a 7.1% increase in ability to predict malignancy using DBT compared to FFDM. Discussion We acknowledge the limitations in terms of design and cohort but the results of this small centre study are in line with previous screening studies and substantiate the use of DBT as a baseline tool in the symptomatic setting.
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Imaging and male breast cancer: Should mammography be employed first-line? How common is breast cancer in men imaged for gynaecomastia? David S J Fenne 1 , Gary Rubin
Introduction
Traditionally mammography has been used as the first-line imaging test in patients with breast symptoms aged over 40 years of either sex. Some centres advocate 'ultrasound first' in men instead. This study assessed whether mammography correctly identified cancers in a 'mammography first' unit, the imaging modalities used and the relationship of gynaecomastia to imaging and breast cancer.
Methods
We looked at male breast cancers from 2010-2014, in addition to the number of men referred to our breast unit who were imaged with mammography, ultrasound, or both in 2014, noting whether they had gynaecomastia.
Results
From 2010-2014, 19 men had breast cancer, 2 bilaterally. All were detected on imaging, including 2 that were unsuspected clinically. Only 1 occurred in a man with clinically simple gynaecomastia. In 2014, 207 men aged 40+ came to our unit and 143 were imaged. 71 had mammography without ultrasound, 63 had both and 9 just ultrasound. Gynaecomastia was the most common indication and finding, being seen in 95 men, representing 68% of those imaged. Assuming 2014 was representative of 2010-2014, 475 men with gynaecomastia needed imaging to find one unsuspected breast cancer, a lower detection rate than in the NHS breast screening programme.
Conclusions
Neither mammography nor ultrasound missed or misclassified any cancers. This study supports using mammography or ultrasound firstline to image men aged 40+, depending on local resources. Gynaecomastia was the major imaging indicator/finding. There should be stricter adherence to guidelines that limit breast imaging for gynaecomastia, as it rarely masks cancer.
Introduction
The primary imaging workload in the breast unit is within the context of the symptomatic fast track clinic or screening assessment clinic. These usually have defined numbers of patients. In addition there is a significant increasing workload of extra patients who require imaging and invasive procedures via other pathways, which we aimed to quantify.
Methods
The data was identified retrospectively from the Computerised Radiology Information System (CRIS) and recorded on a spreadsheet. Information was collected on the number of extra patients who were imaged and reviewed by the Breast Radiologists in addition to their booked workload during the months of May and June 2016. Results Over a two month period there were an additional 60 patients. These patients were referred from a wide variety of departments within the hospital, although the majority were referred through the breast surgeons. A total of 48 ultrasound examinations and 21 mammograms were performed and reported on these patients. The additional procedures performed were also recorded, comprising 6 core biopsies, 2 fine needle aspirations, 4 seroma aspirations and 3 abscess drainages.
Conclusion
There is a significant "extra" workload performed during the working week by Breast Radiologists which may not be reflected in funding streams or be accounted for in job plans. Extra imaging represents a significant workload; the equivalent of 3-4 symptomatic clinics a month. With escalating trends for imaging and a greater reliance on image-guided seroma and abscess drainage, it is likely that this will increase. 310 of these women were in the age-group 35-40 years and 11 cancers were diagnosed. Analysing the data for these 11 cases, 9 had abnormal clinical and ultrasound findings. Mammograms were not crucial to reach the diagnosis. 1 case was clinically benign but had suspicious ultrasound findings. Lesion was occult on subsequent mammograms. In the remaining case, only abnormality was incidental lymphnode which was metastatic on biopsy. Malignant calcification was seen on subsequent mammography. This is the only case where potentially we could have missed the diagnosis.
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Conclusion
In this study, almost all cancers were picked-up on clinical-examination or ultrasound. There was a single case where without upfront mammography we could potentially have missed the diagnosis of cancer. This was picked-up on diligent scanning of the whole quadrant. In our practice, it is safe to limit the use of mammography in the age-group 35-40years and continue using ultrasound as the first line investigation.
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